Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialChristoph Röllig, Gerhard Ehninger, Norbert Frickhofen et al.|The Lancet Oncology|2015Cited by 402
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy—final results of the larynx organ preservation trial DeLOS-IIAndreas Dietz, Ulrich Keilholz, Gunnar Wichmann et al.|Annals of Oncology|2018Cited by 83
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trialChristoph Röllig, Hubert Serve, Richard Noppeney et al.|Leukemia|2021Cited by 58
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemiaCarsten Müller‐Tidow, Petra Tschanter, Christoph Röllig et al.|Leukemia|2015Cited by 49
A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1)Johanna Inhestern, Orlando Guntinas‐Lichius, Harald Schmalenberg et al.|Annals of Oncology|2017Cited by 46